21916 Federal Register / Vol. 76, No. 75 / Tuesday, April 19, 2011 / Notices 

active pharmaceutical ingredient (API) 

form. There are no domestic sources of 

Nabilone in finished drug product form 

available in the United States. The U.S. 

Food and Drug Administration has 

approved this product for medical use 

in the United States. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration, 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than May 19, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745–46, all applicants for 

registration to import a basic class of 

any controlled substance listed in 

schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: April 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–9367 Filed 4–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on September 16, 

2010, Mallinckrodt, Inc., 3600 North 

Second Street, St. Louis, Missouri 

63147, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of 4-Anilino-N-Phenethyl4-Piperidine (ANPP)(8333), a basic class 

of controlled substance listed in 

schedule II. 

The company plans to use this 

controlled substance in the manufacture 

of another controlled substance. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 20, 2011. 

Dated: April 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–9369 Filed 4–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on December 14, 2010, 

Norac Inc., 405 S. Motor Avenue, P.O. 

Box 577, Azusa, California 91702–3232, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Tetrahydrocannabinols (7370) ..... I 

Methamphetamine (1105) ............ II 

Pentobarbital (2270) ..................... II 

Nabilone (7379) ............................ II 

With regard to Gamma 

Hydroxybutyric Acid (2010), 

Tetrahydrocannabinols (7370), and 

Methamphetamine (1105) only, the 

company manufactures these controlled 

substances in bulk solely for domestic 

distribution within the United States to 

customers engaged in dosage-form 

manufacturing. 

With regard to Nabilone (7379) only, 

the company presently manufactures a 

small amount of this controlled 

substance in bulk solely to conduct 

manufacturing process development 

internally within the company. It is the 

company’s intention that, when the 

manufacturing process is refined to the 

point that its Nabilone bulk product is 

available for commercial use, the 

company will export the controlled 

substance in bulk solely to customers 

engaged in dosage-form manufacturing 

outside the United States. The company 

is aware of the requirement to obtain a 

DEA registration as an exporter to 

conduct this activity. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 20, 2011. 

Dated: April 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–9370 Filed 4–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated December 20, 2010, 

and published in the Federal Register 

on December 29, 2010, 75 FR 82073, 

Siegfried (USA), Inc., 33 Industrial Park 

Road, Pennsville, New Jersey 08070, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Dihydromorphine (9145) ............... I 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Drug Schedule 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 76, No. 75 / Tuesday, April 19, 2011 / Notices 21917 

Drug Schedule 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Oxymorphone (9652) ................... II 

Oxycodone (9143) ........................ II 

The company plans to manufacture 

the above listed controlled substances in 

bulk for distribution to its customers. 

Drug codes 1100 (amphetamine) and 

2550 (glutethimide) have been 

withdrawn from the application for 

registration at the request of the 

company. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Siegfried (USA), Inc. to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Siegfried (USA), Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: April 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–9361 Filed 4–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 8, 2010, and 

published in the Federal Register on 

October 20, 2010, (75 FR 64744), 

Cayman Chemical Company, 1180 East 

Ellsworth Road, Ann Arbor, Michigan 

48108, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to manufacture 

small quantities of marihuana 

derivatives for research purposes. In 

reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol. In reference to 

drug code 7370 

(Tetrahydrocannabinols), the company 

will manufacture a synthetic THC. No 

other activity for this drug code is 

authorized for this registration. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cayman Chemical Company to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Cayman Chemical 

Company to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: April 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–9360 Filed 4–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL TRANSPORTATION 

SAFETY BOARD 

Sunshine Act Meeting 

TIME AND DATE: 9:30 a.m., Tuesday, April 

26, 2011. 

PLACE: NTSB Conference Center, 429 

L’Enfant Plaza, SW., Washington, DC 

20594. 

STATUS: The ONE item is open to the 

public. 

MATTER TO BE CONSIDERED: 

8093A Aviation Accident Report 

Crash During Unstabilized Approach, 

Empire Airlines Flight 8284, Avions de 

Transport Re ́gional Aerospatiale Alenia 

ATR 42 320, N902FX, Lubbock, Texas, 

January 27, 2009. 

NEWS MEDIA CONTACT: Telephone: (202) 

314–6100. 

The press and public may enter the 

NTSB Conference Center one hour prior 

to the meeting for set up and seating. 

Individuals requesting specific 

accommodations should contact 

Rochelle Hall at (202) 314–6305 by 

Friday, April 22, 2011. 

The public may view the meeting via 

a live or archived webcast by accessing 

a link under ‘‘News & Events’’ on the 

NTSB home page at http:// 

www.ntsb.gov. 

FOR FURTHER INFORMATION CONTACT: 

Candi Bing, (202) 314–6403 or by e-mail 

at bingc@ntsb.gov. 

Dated: April 15, 2011. 

Candi R. Bing, 

Federal Register Liaison Officer. 

[FR Doc. 2011–9565 Filed 4–15–11; 4:15 pm] 

BILLING CODE 7533–01–P 

NUCLEAR REGULATORY 

COMMISSION 

[NRC–2011–0082] 

Biweekly Notice; Applications and 

Amendments to Facility Operating 

Licenses Involving No Significant 

Hazards Considerations 

I. Background 

Pursuant to Section 189a.(2) of the 

Atomic Energy Act of 1954, as amended 

(the Act), the U.S. Nuclear Regulatory 

Commission (the Commission or NRC) 

is publishing this regular biweekly 

notice. The Act requires the 

Commission publish notice of any 

amendments issued, or proposed to be 

issued and grants the Commission the 

authority to issue and make 

immediately effective any amendment 

to an operating license upon a 

determination by the Commission that 

such amendment involves no significant 

hazards consideration, notwithstanding 

the pendency before the Commission of 

a request for a hearing from any person. 

This biweekly notice includes all 

notices of amendments issued, or 

proposed to be issued from March 24, 

2011, to April 6, 2011. The last biweekly 

notice was published on April 5, 2011 

(76 FR 18801). 

Notice of Consideration of Issuance of 

Amendments to Facility Operating 

Licenses, Proposed No Significant 

Hazards Consideration Determination, 

and Opportunity for a Hearing 

The Commission has made a 

proposed determination that the 

following amendment requests involve 

no significant hazards consideration. 

mstockstill on DSKH9S0YB1PROD with NOTICES